The PANNA study aims to collect pharmacokinetic data in HIV infected pregnant women, using newly developed antiretroviral agents for which no or only limited pharmacokinetic data are available. The study team is collecting pharmacokinetic curves in the 3rd trimester of pregnancy and at 4-6 weeks post-partum. Cord blood will also be collected during delivery to assess the placental passage of the antiretroviral drugs.
The secondary objective of this study is to describe the safety of the antiretroviral agents during pregnancy and the efficacy in terms of viral load response of the mother and prevention of mother-to-child transmission.
The PANNA network is made of 17 centres across 7 European countries. It was initiated by David Burger at the Radboud University Nijmegen Medical Centre in the Netherlands, and it is coordinated by Angela Colbers.
Right now the network focuses on collecting much needed pharmacokinetic data on newly developed antiretroviral drugs during pregnancy in European populations, but could also collect these data for other antiviral compounds such as those for use against hepatitis C.
Please find more about the network and various related studies here.
Go to PANNA publications
This study is funded by Penta. Additional support is provided by NEAT, Merck, BMS, Janssen and CTN.